Manus Rogan of Fountain Healthcare and Peter Crosby, chief executive of Mainstay Medical

CHARLIE TAYLORBack pain group Mainstay Medical, which floated in Paris and Dublin earlier this year, has said it continues to make progress with its R(...)

The bell on the decommissioned trading floor of the Irish Stock Exchange

The number of trades dealt on the Irish Stock Exchange rose by 32 per cent in the first six months of 2014.Some 2.2 million equity trades took place d(...)

Manus Rogan of Fountain Healthcare and Peter Crosby, chief executive of Mainstay Medical.

Back pain group Mainstay Medical has floated in Paris and Dublin in an IPO that values the early stage medical device company (...)

Mainstay Medical chief executive Peter Crosby.

Irish medical device company Mainstay Medical plans to raise up to €26.4 million in a stock market flotation (...)

 Peter Crosby, chief executive of Mainstay Medical. Photograph: Nick Bradshaw

Mainstay Medical, an Irish-based group focused on addressing chronic back pain, has announced it plans to float on the (...)

Trials are starting initially in Australia as the regulatory path there was considered quicker to negotiate, according to the company’s Australian chief executive, Peter Crosby.

It has taken three years to get a product to trials: Mainstay Medical hopes that within another two, it will have a device on the market in Eur(...)

“The results are, for us at least, pretty exciting. They show that the therapy that’s delivered by our product appears to work and the results have certainly captured the attention of the clinical community with which we work,” said Mainstay chief executive Peter Crosby.

Mainstay Medical, an Irish medtech company targeting chronic lower back pain, is starting clinical trials on its Reactiv8 implantable device. (...)